Ultragenyx Pharmaceutical Inc. (RARE): Valuation
TTM figures as of June 30, 2026
Ultragenyx Pharmaceutical Inc. trades at a -34.69% free-cash-flow yield. That FCF yield is higher than 0% of its own month-end history back to 2014.
Earnings yield -41.56%.
152 month-end valuation observations are on file, starting January 2014.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is RARE cheap versus its own history?
Ultragenyx Pharmaceutical Inc. trades at a -34.69% free-cash-flow yield. That FCF yield is higher than 0% of its own month-end history back to 2014.
What is RARE's free-cash-flow yield?
Ultragenyx Pharmaceutical Inc. currently yields -34.69% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.